Scientific Program
Friday, September 12, 2025
| 09:00-09:15 |
Congress Opening |
Hall A |
| Chairpersons |
|
|
Welcome from Congress chairpersons
|
| 09:15-10:30 |
Session 1: Neoadjuvant therapy |
Hall A |
| Chairpersons |
|
09:15-09:45
09:15
09:25
09:35 |
Debate: That cT1cN0 HER2+ve should have Neoadjuvant Systemic Therapy (NAST)
Yes:
No:
Discussion |
| 09:45-10:00 |
Didactic: Imaging before and during NAST |
10:00-10:30
10:00
10:10
10:20 |
Debate: That endocrine therapy is neoadjuvant treatment of choice for ER+ve/HER2-ve disease
Yes:
No:
Discussion |
| 10:30-11:00 |
Coffee break, poster viewing and exhibition visit |
| 11:00-12:00 |
Session 2: Surgery |
Hall A |
| Chairpersons |
|
11:00-11:30
11:00
11:10
11:20 |
Debate: Breast conservation, not mastectomy, should be the standard of care for T2 cancers
Yes:
No:
Discussion |
11:30-12:00
11:30
11:40
11:50 |
Debate: Radiation therapy should be given to all women under 70 having breast conservation for invasive cancer
Yes:
No:
Discussion |
| 12:00-13:30 |
Session 3: HER2+ve disease |
Hall A |
| Chairpersons |
|
12:00-12:35
12:00
12:10
12:20 |
Debate: Do anthracyclines still have a place in the treatment of early stage HER2+ve BC?
Yes:
No:
Discussion |
| 12:35-12:55 |
Didactic: Understanding HER2 low disease – how to diagnose/how to treat? |
12:55-13:30
12:55
13:05
13:15 |
Debate: Axillary radiation is better than surgery after neoadjuvant treatment for node positive disease
Yes:
No:
Discussion |
| 13:30-14:30 |
Lunch Symposium:
Lunch will be served to session participants only. |
Hall A |
| Chairperson |
|
|
|
|
|
|
|
| 13:30-14:30 |
Lunch break, poster viewing and exhibition visit |
| 14:30-15:00 |
Session 4: Case Discussions |
Hall A |
| Chairpersons |
|
|
|
| 15:00-16:00 |
Session 5: ER+ breast cancer
|
Hall A |
| Chairpersons |
|
15:00-15:30
15:00
15:10
15:20
|
Debate: Endocrine therapy intensity
Yes:
No:
Discussion |
15:30-16:00
15:30
15:40
15:50 |
Debate: Postmenopausal women with clinical T1N0 ER+ breast cancer do not need axillary surgery
Yes:
No:
Discussion |
| 16:00-16:30 |
Coffee break, poster viewing and exhibition visit |
| 16:30-17:30 |
Session 6: HR+ve Metastatic Breast Cancer (MBC) |
Hall A |
| Chairpersons |
|
| 16:30-17:00 |
Didactic: What to do after progression of ER+ breast cancer: Change ET, CDK4/6i or SERDS? |
17:00-17:30
17:00
17:10
17:20 |
Debate: Endocrine therapy should be given as 1st line therapy for ALL patients with ER+ve MBC
Yes:
No:
Discussion |
| 17:30-19:00 |
Poster Session and Networking Reception |
Saturday, September 13, 2025
| 08:30-09:30 |
Breakfast Industry Symposium
|
Hall A |
|
Light refreshments will be served to session participants only. |
| 09:30-10:30 |
Session 7: Screening |
Hall A |
| Chairpersons |
|
09:30-10:00
09:30
09:40
09:50 |
Debate: That all countries should invest in population-based mammographic screening
Yes:
No:
Discussion |
| 10:00-10:30 |
Didactic: Screening methods to cover risk assessment and non-mammographic technologies relevant to Latin America |
| 10:30-11:00 |
Coffee break, poster viewing and exhibition visit |
| 11:00-12:30 |
Session 8: Triple negative breast cancer |
Hall A |
| Chairpersons |
|
11:00-11:30
11:00
11:10
11:20 |
Debate: That all stage 2 TNBC patients should be treated according to the Keynote 522 regimen
Yes:
No:
Discussion |
| 11:30-12:00 |
TNBC subtypes: How do we use them to help patient outcomes? |
12:00-12:30
|
Case discussions |
| 12:30-13:30 |
Session 9: Reducing the risk |
Hall A |
| Chairpersons |
|
12:30-13:00
12:30
12:40
12:50 |
Debate: All women under 50 with gene mutations should be offered bilateral mastectomy
Yes:
No:
Discussion |
13:00-13:30
13:00
13:10
13:20 |
Debate: All women presenting with nodal disease should have radiation therapy after mastectomy
Yes:
No:
Discussion |
| 13:30-14:30 |
Lunch Symposium:
Lunch will be served to session participants only. |
Hall A |
| Chairperson |
|
|
|
|
|
|
|
| 13:30-14:30 |
Lunch break, poster viewing and exhibition visit |
| 14:30-16:00 |
Session 10: Adjuvant endocrine therapy |
Hall A |
| Chairpersons |
|
14:30-15:10
14:30
14:40
14:50
15:00 |
Pitching the test in five minutes: Why this test is “best”?
PAM50
Oncotype/ODX
Mammaprint
Pathology |
| 15:10-15:30 |
Didactic: Risk assessment for ER+ breast cancer |
15:30-16:00
15:30
15:40
15:50 |
Debate: That all young women treated with OFS should be given an aromatase inhibitor
Yes:
No:
Discussion |
| 16:00-17:00 |
Session 11: Locoregional management |
Hall A |
| Chairpersons |
|
16:00-16:30
16:00
16:10
16:20 |
Debate: That patients with heavy axillary nodal disease pre-NACT should have axillary dissection irrespective of response to NACT
Yes:
No:
Discussion |
| 16:30-17:00 |
Case discussions focusing on Locoregional management |
| 17:00-17:15 |
Congress closing and Award presentation |
Hall A |
| Chairpersons |
|
- Program is subject to change
